FAK is also a driver of cholangiocarcinogenesis, and in vivo experiments have shown that ablation of FAK significantly delayed the initiation of Akt/YAP-driven intrahepatic cholangiocarcinoma (iCCA) in mice. Here, PTK2 is linked to intrahepatic cholangiocarcinoma.